PMID- 30464490
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1176-6336 (Print)
IS  - 1178-203X (Electronic)
IS  - 1176-6336 (Linking)
VI  - 14
DP  - 2018
TI  - Mycophenolate therapy in interstitial pneumonia with autoimmune features: a 
      cohort study.
PG  - 2171-2181
LID - 10.2147/TCRM.S173154 [doi]
AB  - OBJECTIVES: International experts recently characterized interstitial pneumonia 
      with autoimmune features (IPAF) as a provisional diagnosis for patients with 
      interstitial lung disease who have characteristics of autoimmune disease but do 
      not meet criteria for a specific autoimmune disease. We describe clinical 
      characteristics of IPAF patients and examine responses to mycophenolate as a 
      therapy for IPAF. METHODS: This retrospective cohort included adult patients 
      meeting European Respiratory Society/American Thoracic Society classification 
      criteria for IPAF. Sociodemographic, clinical, and pulmonary function test data 
      were abstracted for patients with and without mycophenolate treatment and 
      followed longitudinally from interstitial lung disease diagnosis for change in 
      pulmonary function test results. RESULTS: We identified 52 patients who met 
      criteria for IPAF. Of 52 IPAF patients, 24 did not receive mycophenolate and 28 
      did, with median time to mycophenolate treatment 22 months. Changes in FVC% and 
      percentage predicted lung diffusion capacity for carbon monoxide (D(LCO)%) 
      between the mycophenolate-treated and untreated groups were not significantly 
      different (FVC% change P=0.08, D(LCO)% change P=0.17). However, there was a trend 
      toward more rapid baseline decline of both FVC% and D(LCO)% in the 
      mycophenolate-treated cohort before vs after mycophenolate therapy. The slope of 
      both FVC% and D(LCO)% values improved after onset of mycophenolate exposure for 
      the treated group, although this finding was not statistically significant. 
      CONCLUSION: Patients with IPAF might benefit from mycophenolate therapy. Larger 
      prospective clinical trials are needed to evaluate the efficacy of mycophenolate 
      for patients who meet criteria for IPAF.
FAU - McCoy, Sara S
AU  - McCoy SS
AD  - Division of Rheumatology, Department of Internal Medicine, School of Medicine and 
      Public Health, University of Wisconsin, Madison, WI 53705, USA, 
      ssmccoy@medicine.wisc.edu.
FAU - Mukadam, Zubin
AU  - Mukadam Z
AD  - Division of Pulmonary and Critical Care, Department of Internal Medicine, School 
      of Medicine and Public Health, University of Wisconsin, Madison, WI 53705, USA.
FAU - Meyer, Keith C
AU  - Meyer KC
AD  - Division of Pulmonary and Critical Care, Department of Internal Medicine, School 
      of Medicine and Public Health, University of Wisconsin, Madison, WI 53705, USA.
FAU - Kanne, Jeffrey P
AU  - Kanne JP
AD  - Department of Radiology, University of Wisconsin, Madison, WI 53792-3252, USA.
FAU - Meyer, Cristopher A
AU  - Meyer CA
AD  - Department of Radiology, University of Wisconsin, Madison, WI 53792-3252, USA.
FAU - Martin, Maria D
AU  - Martin MD
AD  - Department of Radiology, University of Wisconsin, Madison, WI 53792-3252, USA.
FAU - Sampene, Emmanuel
AU  - Sampene E
AD  - Department of Biostatistics, School of Medicine and Public Health, University of 
      Wisconsin, Madison, WI, USA.
FAU - Aesif, Scott W
AU  - Aesif SW
AD  - Department of Pathology, University of Wisconsin, Madison, WI 53792-3252, USA.
FAU - Rice, Laurie N
AU  - Rice LN
AD  - Department of Pulmonology, SSM Health Dean Medical Group, Madison, WI 53715, USA.
FAU - Bartels, Christie M
AU  - Bartels CM
AD  - Division of Rheumatology, Department of Internal Medicine, School of Medicine and 
      Public Health, University of Wisconsin, Madison, WI 53705, USA, 
      ssmccoy@medicine.wisc.edu.
LA  - eng
PT  - Journal Article
DEP - 20181101
PL  - New Zealand
TA  - Ther Clin Risk Manag
JT  - Therapeutics and clinical risk management
JID - 101253281
PMC - PMC6219314
OTO - NOTNLM
OT  - autoimmune disease
OT  - connective tissue disease
OT  - interstitial lung disease
OT  - mycophenolate
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/11/23 06:00
MHDA- 2018/11/23 06:01
PMCR- 2018/11/01
CRDT- 2018/11/23 06:00
PHST- 2018/11/23 06:00 [entrez]
PHST- 2018/11/23 06:00 [pubmed]
PHST- 2018/11/23 06:01 [medline]
PHST- 2018/11/01 00:00 [pmc-release]
AID - tcrm-14-2171 [pii]
AID - 10.2147/TCRM.S173154 [doi]
PST - epublish
SO  - Ther Clin Risk Manag. 2018 Nov 1;14:2171-2181. doi: 10.2147/TCRM.S173154. 
      eCollection 2018.